Registry Following Treatment and Outcomes of Chinese Adults With Chronic Kidney Disease
Collects real-world data on how Chinese adults with chronic kidney disease are treated.
Plain-language title generated from the registry record
Registry title: A Prospecitve Multicenter, Observational Registry Study
Key facts
- Where
- Anning, Yunnan - South Region, Beijing, Beijing, Cangzhou, Hebei - North Region, Caoxian County, Shandong Province, Changzhou, Jiangsu Province, Chengdu, Sichuan Province, Chongqing, Chongqing, Chongqing, Sichuan Province, Dalian, Liaoning, Dongguan, Guangdong, Foshan, Guangdong, Fuzhou, Fujian, Ganzhou, Jiangxi, Guangzhou, Guangdong, Guiyang, Guizhou, Hangzhou, Zhejiang, Harbin, Heilongjiang, Hohhot, Inner Mongolia, Huai An, Jiangsu Province, Jiaozuo, Henan Province, Jinan, Shandong Province, Jining, Shandong Province, Jiujiang, Jiangxi, Kunming, Yunnan, Nanchang, Jiangxi, Nanjing, Jiangsu Province, Nanning, Guangxi, Nanping, Fujian, Nantong, Jiangsu Province, Nanyang, Henan Province, Shanghai, Shanghai, Shangqiu, Henan Province, Shantou, Guangdong, Shaoxing, Zhejiang, Shenyang, Liaoning, Shenzhen, Guangdong, Shijiazhuang, Hebei, Suzhou, Jiangsu Province, Taiyuan, Shanxi, Taizhou, Jiangsu, Tianjin, Tianjin, Tonglu County, Zhejiang, Urumqi, Xinjiang, Weifang, Shandong Province, Wuhan, Hubei, XI An, Shaanxi Province, Xiamen, Fujian, Xiangyang, Hubei, Xiantao, Hubei, Xuancheng, Anhui, Yinchuan, Ningxia Hui Autonomous Region, Yiwu,Zhejiang, Zhangzhou, Fujian, Zhenjiang, Jiangsu Province, Zhoushan, Zhejiang, Zhuji, Zhejiang, and Zibo, Shandong Province, ChinaSee the 57 sites
Where in China
- Anning, Yunnan - South RegionAnning, Yunnan - South Region, ChinaTaking people
- Beijing, BeijingBeijing, Beijing, ChinaTaking people
- Cangzhou, Hebei - North RegionCangzhou, Hebei - North Region, ChinaTaking people
- Caoxian County, Shandong ProvinceCaoxian County, Shandong Province, ChinaTaking people
- Changzhou, Jiangsu ProvinceChangzhou, Jiangsu Province, ChinaTaking people
- Chengdu, Sichuan ProvinceChengdu, Sichuan Province, ChinaTaking people
- Chongqing, ChongqingChongqing, Chongqing, ChinaTaking people
- Chongqing, Sichuan ProvinceChongqing, Sichuan Province, ChinaTaking people
- Dalian, LiaoningDalian, Liaoning, ChinaNot yet recruiting
- Dongguan, GuangdongDongguan, Guangdong, ChinaTaking people
- Foshan, GuangdongFoshan, Guangdong, ChinaTaking people
- Fuzhou, FujianFuzhou, Fujian, ChinaTaking people
- Ganzhou, JiangxiGanzhou, Jiangxi, ChinaTaking people
- Guangzhou, GuangdongGuangzhou, Guangdong, ChinaTaking people
- Guiyang, GuizhouGuiyang, Guizhou, ChinaTaking people
- Hangzhou, ZhejiangHangzhou, Zhejiang, ChinaTaking people
- Harbin, HeilongjiangHarbin, Heilongjiang, ChinaTaking people
- Hohhot, Inner MongoliaHohhot, Inner Mongolia, ChinaNot yet recruiting
- Huai An, Jiangsu ProvinceHuai An, Jiangsu Province, ChinaTaking people
- Jiaozuo, Henan ProvinceJiaozuo, Henan Province, ChinaTaking people
- Jinan, Shandong ProvinceJinan, Shandong Province, ChinaTaking people
- Jining, Shandong ProvinceJining, Shandong Province, ChinaTaking people
- Jiujiang, JiangxiJiujiang, Jiangxi, ChinaTaking people
- Kunming, YunnanKunming, Yunnan, ChinaTaking people
- Nanchang, JiangxiNanchang, Jiangxi, ChinaTaking people
- Nanjing, Jiangsu ProvinceNanjing, Jiangsu Province, ChinaTaking people
- Nanning, GuangxiNanning, Guangxi, ChinaTaking people
- Nanping, FujianNanping, Fujian, ChinaTaking people
- Nantong, Jiangsu ProvinceNantong, Jiangsu Province, ChinaTaking people
- Nanyang, Henan ProvinceNanyang, Henan Province, ChinaTaking people
- Shanghai, ShanghaiShanghai, Shanghai, ChinaTaking people
- Shangqiu, Henan ProvinceShangqiu, Henan Province, ChinaTaking people
- Shantou, GuangdongShantou, Guangdong, ChinaTaking people
- Shaoxing, ZhejiangShaoxing, Zhejiang, ChinaTaking people
- Shenyang, LiaoningShenyang, Liaoning, ChinaNot yet recruiting
- Shenzhen, GuangdongShenzhen, Guangdong, ChinaTaking people
- Shijiazhuang, HebeiShijiazhuang, Hebei, ChinaTaking people
- Suzhou, Jiangsu ProvinceSuzhou, Jiangsu Province, ChinaTaking people
- Taiyuan, ShanxiTaiyuan, Shanxi, ChinaTaking people
- Taizhou, JiangsuTaizhou, Jiangsu, ChinaTaking people
- Tianjin, TianjinTianjin, Tianjin, ChinaTaking people
- Tonglu County, ZhejiangTonglu County, Zhejiang, ChinaTaking people
- Urumqi, XinjiangUrumqi, Xinjiang, ChinaTaking people
- Weifang, Shandong ProvinceWeifang, Shandong Province, ChinaTaking people
- Wuhan, HubeiWuhan, Hubei, ChinaTaking people
- XI An, Shaanxi ProvinceXI An, Shaanxi Province, ChinaTaking people
- Xiamen, FujianXiamen, Fujian, ChinaTaking people
- Xiangyang, HubeiXiangyang, Hubei, ChinaTaking people
- Xiantao, HubeiXiantao, Hubei, ChinaTaking people
- Xuancheng, AnhuiXuancheng, Anhui, ChinaTaking people
- Yinchuan, Ningxia Hui Autonomous RegionYinchuan, Ningxia Hui Autonomous Region, ChinaTaking people
- Yiwu,ZhejiangYiwu,Zhejiang, ChinaTaking people
- Zhangzhou, FujianZhangzhou, Fujian, ChinaTaking people
- Zhenjiang, Jiangsu ProvinceZhenjiang, Jiangsu Province, ChinaTaking people
- Zhoushan, ZhejiangZhoushan, Zhejiang, ChinaTaking people
- Zhuji, ZhejiangZhuji, Zhejiang, ChinaTaking people
- Zibo, Shandong ProvinceZibo, Shandong Province, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07481526
- Record updated
- 13 August 2026
- Original description
This is a prospective, multicenter, observational registry study designed to collect data to deepen the understanding of CKD therapeutics, changes in clinical practice, cardiorenal risk outcomes and differences in treatment approaches in Chinese CKD patients.Read full original descriptionShow less
A Multicenter Real-World Registry of Characteristics, Treatment Strategies, and Clinical Outcomes in Chinese Adults With Chronic Kidney Disease
This is a prospective, multicenter, observational registry study designed to collect data to deepen the understanding of CKD therapeutics, changes in clinical practice, cardiorenal risk outcomes and differences in treatment approaches in Chinese CKD patients.
Inclusion: Male or female patients aged ≥18 years; Willing and able to provide written informed consent to participate in the study; Confirmed CKD diagnosis at enrolment, defined by at least one of the following:; eGFR <60 mL/min/1.73 m² for ≥3 months, OR; Evidence of kidney damage (e.g., UACR ≥30 mg/g or UPCR ≥150 mg/g, structural abnormality on imaging, or kidney biopsy findings consistent with chronic kidney injury) persisting for ≥3 months.
Exclusion: Currently enrolled in any interventional clinical trial or receiving investigational therapy within 3 months of enrollment; Severe cardiac disease: life-threatening arrhythmias, or recent MACE (Myocardial infarction (MI), stroke, CV death) within the past 3 months; Presenting with ESRD, RRT, acute kidney injury (AKI), acute kidney disease (i.e., kidney injury or a decline in renal function persisting for ≤3 months) as a primary disease condition at enrollment; Having a life-threatening comorbidity with life expectancy < 2 years; Pregnant or breastfeeding women.